Assembly Biosciences(US:ASMB)2025-11-10 21:10Financial Performance - Assembly Biosciences reported a net loss of $9.2 million, or $0.72 per share, for Q3 2025, compared to a net loss of $9.6 million, or $1.51 per share, in Q3 2024[12]. - Cash, cash equivalents, and marketable securities totaled $232.6 million as of September 30, 2025, compared to $75.0 million as of June 30, 2025, providing a cash runway projected to fund operations into late 2027[8]. - Assembly Biosciences raised $175 million in gross proceeds from equity financing, enhancing its financial position to support ongoing and future clinical development[3]. - Research and development expenses increased to $16.6 million for Q3 2025, compared to $13.5 million in Q3 2024, primarily due to spending on the HSV program[12]. - Total operating expenses for Q3 2025 were $21.7 million, up from $17.8 million in the same period in 2024[12]. Research and Development - Revenue from collaborative research with Gilead was $10.8 million for Q3 2025, up from $6.8 million in the same period in 2024, reflecting increased research and development activities[12]. - Positive interim results were released from the Phase 1b study of ABI-5366, showing significant reductions in HSV-2 shedding and genital lesion rates in participants with recurrent genital herpes[4]. - Enrollment was completed in the ongoing Phase 1b studies for both ABI-5366 and ABI-1179, with additional data updates expected by the end of the year[4]. - The Phase 1a study of ABI-6250 demonstrated a pharmacokinetic profile supporting once-daily dosing, leading to its progression into Phase 2 evaluation[9]. - The initiation of a Phase 2 clinical study of ABI-5366 is anticipated in mid-2026[9].